Glycoproteomics-based Liquid-biopsy Laboratory Developed Test (LDT) Development Services

Glycoproteomics represents a cutting-edge field within proteomics that focuses on the comprehensive characterization of glycoproteins and their glycan structures. As a leader in this specialized area, Creative Biolabs offers a series of glycoproteomics-based liquid-biopsy laboratory-developed test (LDT) services for a variety of cancer types at a clinically meaningful scale by leveraging the advanced platform and extensive experience.

Glycoproteomics-based Liquid-biopsy in Precision Medicine

Aberrant protein glycosylation and alterations in glycans have been linked to the initiation and advancement of a wide spectrum of diseases. Glycoproteins with specific glycoforms can serve as valuable biomarkers and provide critical information for cancer diagnosis and treatment decisions through mass spectrometry (MS)-based glycoproteomics. Over the last decade, liquid biopsy has emerged as a desirable alternative in cancer management, fluid specimens like blood or other body fluids offer several advantages over traditional tissue biopsies, such as relative ease of attainment, sequential sampling, and minimally invasive procedure, making them a valuable tool in the monitoring of the disease and treatment response. Therefore, glycoproteomics-based liquid-biopsy analysis holds great promise in advancing our understanding of diseases and ultimately leads to more effective and precise healthcare interventions.

Fig.1 Roles of glycoproteomics in precision medicine.

Glycoproteomics-based Liquid-biopsy LDT Services at Creative Biolabs

With well-constructed detection techniques and industry-leading expertise, Creative Biolabs is confident in providing a diversity of glycoproteomics-based liquid biopsy LDT services and offering comprehensive analysis for various cancer types for our clients all over the world. Our LDT services include but are not limited to the following cancer types:

Nonalcoholic Steatohepatitis (NASH)

Hepatocellular Carcinoma (HCC)

Non-Small Cell Lung Carcinoma (NSCLC)

Advanced Adenoma

Pancreas Carcinoma

Colorectal Cancer

Renal Cell Carcinoma

Prostate Cancer

Nasopharyngeal Carcinoma

Glycoproteomics-based Liquid-biopsy LDT Development at Creative Biolabs

Creative Biolabs has developed powerful platforms for glycoproteomics-based liquid-biopsy LDT development aimed to characterize and quantify glycoproteins as well as the attached glycan structures.

Our LDT development involves advanced separation and enrichment methodologies from complex serum or other liquid samples, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis with carefully chosen fragmentation methods. Furthermore, we provide comprehensive bioinformatic analysis such as differential expression analysis, functional analysis, and protein interaction networks. Our approach integrates these analyses with other available omics datasets, including proteomics and transcriptomics, facilitating a holistic understanding of intricate cellular processes and networks.

Fig.2 Workflow of glycoproteomics-based liquid-biopsy LDT development.

Advantages

Non-invasiveness and serial testing

High resolution and sensitivity

In-depth bioinformatic analysis

Professional technical team

Published Data

Part 1:

Technology: Glycoproteomic analysis

Journal: Journal of Proteome Research

Published: 2022

Results: Altered protein glycosylation with higher relative abundance of core fucosylation, branching, and sialylation of glycans was observed in NASH and HCC patients as compared to healthy controls.

Fig.3 Serum glycopeptide biomarkers in NASH and HCC samples.¹

Part 2:

Technology: Glycoproteomic analysis

Journal: Frontiers in Immunology

Published: 2023

Results: Glycoproteomic profiling of blood provides a promising novel approach to guide the clinical use of ICI therapy in patients with metastatic melanoma.

Fig.4 Fucosylation and sialylation signatures in ICI therapy.²

Creative Biolabs, as a renowned leader in glycoproteomic analysis, offers a wealth of experience and expertise in this dynamic field. Our dedicated glycoproteomic services and collaborative consultation enable us to tailor a strategic timeline and operation plan to meet your unique requirements. Contact us today and let us be your partner in advancing your glycoproteomic endeavors.

References

Ramachandran, Prasanna, et al. "Serum glycoprotein markers in nonalcoholic steatohepatitis and hepatocellular carcinoma." Journal of Proteome Research 21.4 (2022): 1083-1094.
Pickering, Chad, et al. "Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy." Frontiers in Immunology 14 (2023): 1187332.

For Research Use Only.

NASH NSCLC Pancreas Carcinoma Renal Cell Carcinoma Nasopharyngeal Carcinoma HCC Advanced Adenoma Colorectal Cancer Prostate Cancer